

**BIOGRAPHICAL SKETCH**

Provide the following information for the Senior/key personnel and other significant contributors in the order listed on Form Page 2.  
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME <b>David S. Hanson, M.D.</b>		POSITION TITLE Clinical Research Lead Investigator Mary Bird Perkins Cancer Center component and sub-component sites	
eRA COMMONS USER NAME Oncology			
EDUCATION/TRAINING <i>(Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)</i>			
INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY
University of Denver, Denver, Colorado	BS	1977-1981	Biological Sciences
University of Colorado School of Medicine, Denver, Colorado	MD	1981-1985	Medicine
University of Colorado Health Sciences Center, Denver, Colorado	Intern	1985-1986	Internal Medicine
University of Colorado Health Sciences Center	Resident	1986-1988	Internal Medicine
University of Colorado Health Sciences Center	Fellow	1988-1990	Hematology /Oncology

**A. Personal Statement**

As the Chairman of the Cancer Committee at Mary Bird Perkins-Our Lady of the Lake Cancer Center (MBP-OLOL CC) for over 15 years, I have more than 25 years of clinical, programmatic, and administrative leadership, and have spent a substantial amount of time directly involved in NCCCP activities since our site was selected in 2007, attending each annual NCCCP meeting and collaborating with the 30 sites as related to clinical research and quality of care initiatives. As a practicing physician in a core oncology practice group, Louisiana Hematology Oncology Associates, I have contributed significant work directly related to NCCCP, such as serving as Chair of the Cancer Committee, and actively participating as a full member of our Colorectal and Lung Multidisciplinary Care Teams. I have served on the hospital's Medical Executive Committee for the past several years and moderate tumor conferences, provide leadership for quality and evidence based initiatives within our American Society of Clinical Oncology's Quality Oncology Practice Initiative certified medical oncology practice, and serve as PI for both pharmaceutical and cooperative group clinical trials through the Cancer Center's affiliation with the LSU Minority-Based Clinical Cooperative Oncology Program in New Orleans, LA.. For the past 20 years, I have served on the LSU faculty, providing direct patient care and graduate medical education at Earl K. Long Medical Center in Baton Rouge, an LSU hospital that served as the "safety net" provider in our region. Through a public-private partnership, LSU contracted with Our Lady of the Lake in 2013 for cancer care services, and I continue to provide cancer care for the underserved, under-insured, and uninsured patient population that was once served by Earl K. Long, at LSU North Baton Rouge Oncology Clinic, an affiliate of Our Lady of the Lake. I have extensive experience in oncology clinical research and have contributed to the development of an active clinical research program. I am a top accruing physician to NCI sponsored clinical trials and continue to work closely and lead the clinical research efforts for the MBP-OLOL Cancer Center with clinical research portfolio development, and continue to assure that the NCCCP trials selected by the NCCCP Clinical Trial Portfolio Workgroup are a top accruing priority when appropriate for our patient population. My role for the Gulf South-Minority Based-NCORP will be the Clinical Trial Lead Investigator for Mary Bird Perkins Cancer Center component site and sub-component sites, as I have extensive experience providing direct care to medically underserved populations diagnosed with the dreaded disease of cancer.

**B. Positions and Honors.****Positions**

- 1987-1990 - Denver Veteran's Administration Hospital, Attending Physician, Emergency Room, Denver Colorado  
1989-1990 - Hospice of St. John, Lakewood, Colorado

Program Director/Principal Investigator (Last, First, Middle): Ochoa, Augusto C.

- 1990-1993 - Ochsner Clinic of Baton Rouge, Staff Physician, Division of Internal Medicine, Section of Hematology & Medical Oncology, Baton Rouge, Louisiana
- 1993-1994 - Mayo Clinic of Jacksonville, Senior Associate Consultant, Department of Internal Medicine, Section of Hematology & Medical Oncology
- 1994-2012 - Louisiana Hematology Oncology Associates, Mary Bird Perkins Cancer Center, Medical Oncology, Baton Rouge, Louisiana
- 2013 - present - Our Lady of the Lake Physician Group, Louisiana Hematology Oncology Associates, Medical Oncology, Baton Rouge, Louisiana

**Honors:**

University of Denver

- 1977-1978 Outstanding Student, General Chemistry
- 1977-1981 Honors Scholarship
- 1977-1981 Leta B. Swartz, Premedical Scholarship
- 1977-1981 4.0 Honor Society
- 1979-1980 Outstanding Student, General Physics
- 1980-1981 Outstanding Senior Thesis: "The Effects of Biphenyl on Tetrahymena Pyriformis"

University of Colorado – School of Medicine

- 1985 Gold Reflex Hammer Award – Outstanding Fourth Year Student in Neurology
- 1985 Lange Award – Outstanding Performance in Internal Medicine

Baton Rouge Business Report

- 1997 "Top 40 Under 40"

**C. Selected peer-reviewed publications (in chronological order).**

1. Brooks, B.J., Hanson, D.S., Cryer, P.A., Hubbard, W.J., Hooper, D., Erythropoietin Therapy for Sickle Cell Anemia in Jehovah's Witnesses, *South Med. Jour.* 84:1416, 1991.
2. Hanson, D.S. and Brooks, B.J., Innovative Therapies in Hematology and Oncology. *Med. Clin. N. Amer.* 76(5):1169, 1992.
3. Gralla, R.S., Kardinal, C.G., Clark, R.A., Otten, M.C., and Hanson, D.S. Enhancing the Safety, Efficacy, and Dose Intensity of Vinorelbine (Navelbine) in Combination Chemotherapy Regimens. *Proc ASCP* 12:336, 1993.
4. Hanson, D.S., Low-Grade and High-Grade Non-Hodgkin's Lymphomas in Hematology and Oncology Secrets, edited by Wood, M.E., and Bunn, P.A., pp. 134-138, Hanley and Belfus/Mosby, 1994.
5. Hanson, D.S. and Leggett, C.T. Severe hypotension following inadvertent intravenous administration of interferon alfa-2a. *Annals of Pharmacotherapy.* 31:371-372, 1997.
6. Hanson, D.S., Aggressive and Highly Aggressive Non-Hodgkin's Lymphomas and Evaluation of Leukocytosis in Hematology and Oncology Secrets, edited by Wood, M.E., pp 137-140 and pp. 28-31, Second Edition, 1999.

**Research Support Open**

Multiple NCI sponsored cooperative group clinical trials and pharmaceutical sponsored studies such as:

KangLaiTe USA: Sub-Investigator for Phase 2b for advanced Pancreatic Cancer trial (2009 – Present)

Celgene Corporation, Inc.: Sub-Investigator for Phase IV for Observational trial (2009 – Present)

Celgene Corporation, Inc.: Sub-Investigator for Phase IV for Observational trial (2010 – Present)

Program Director/Principal Investigator (Last, First, Middle): Ochoa, Augusto C.

Galena Biopharma: Sub-Investigator for Phase III for early stage Breast Cancer trial (2011 – Present)

CALGB 90601 – Sub-Investigator for Phase III Randomized Study for Advanced Transitional Cell Carcinoma (2010 - Present)

CALGB 90203 - Sub-Investigator for Phase III Randomized Study for localized prostate cancer (2010-Present)

CALGB/SWOG C80702: Sub-Investigator for Phase III Study for Resected Stage III Colon Cancer (2010-present)

### **Research Support Completed Within 5 Years**

Genentech: Principal Investigator for Phase IIIB Advanced NSCLC Trial (2000 – 2008)

Genentech: Sub-Investigator for Phase II NSCLC Trial, Sub-Investigator for Phase III Metastatic Breast Trial (2000-2009)

Genentech: Sub-Investigator for Phase IV Observational Trial ( 2000-2012)

Amgen: Principal Investigator for Phase II Advanced Colorectal Trial (2003-2008)

Amgen: Sub-Investigator for Phase II Metastatic Colorectal Trial (2003-2010)

American Bioscience, Inc.: Sub-Investigator for Phase II Metastatic Renal Trial (2005-2008)

Pfizer: Sub-Investigator for Phase II Renal Trial (2006-2010)

Berlex: Sub-Investigator for Phase II Metastatic Prostate Trial (2006-2009)

Pharmion: Sub-Investigator for Phase IV observational trial (2007-2010)

GPC Biotech: Sub-Investigator for Phase III Prostate Cancer trial (2007-2008)

ACORN: Sub-Investigator for Phase 2b locally Advanced/Metastatic Breast Cancer trial (2008-2010)

Synta: Principal Investigator for Phase III for Metastatic Melanoma trial (2008-2010)

ACORN: Sub-Investigator for Phase 2b local advanced/metastatic breast cancer trial (2008-2011)

Eli Lilly and Company: Sub-Investigator for Phase III advanced NSCLC trial, Sub-Investigator for Phase III Stage IV NSCLC trial (2010 – 2012)

Onconova Therapeutics, Inc.: Sub-Investigator for Phase III MDS trial (2011-2012)

Cell Therapeutics, Inc., Sub-Investigator for Phase III NHL trial (2011-2013)

Sanofi-Aventis U.S. Inc.: Sub-Investigator for Phase IV observational trial (2011-2012)

Abraxis Bioscience, LLC.: Sub-Investigator for Phase III for Metastatic Pancreatic Cancer trial ( 2011 – 2012)

Oncolytics Biotech Inc.: Sub-Investigator for Phase III for Head and Neck Cancer trial (2011 – 2012)

SciClone Pharmaceuticals, Inc.: Sub-Investigator for Phase 2b for Head and Neck Cancer trial (2011-2013)

Teva Pharmaceutical Industries: Principal Investigator for Phase III Prostate Cancer trial (2010 – 2013)

Eli Lilly and Company: Sub-Investigator for Phase II for Ovarian, NSCLC, Prostate, Colorectal, GE, and Head and Neck Cancer trial (2011-2012)

Taiho Pharma USA: Sub-Investigator for Phase III for metastatic Colorectal Cancer trial (2012 – 2013)

NewLink Genetics Corporation: Sub-Investigator for Phase III for Surgically Resected Pancreatic Cancer trial (2012 – 2013)

BMS: Sub-Investigator for Phase III for ED-SCLC Cancer trial (2012 – 2013)

CALGB 40101: Sub-Investigator for Phase III Randomized Study for Breast Cancer (2002-2010)

CALGB 40302: Sub-Investigator for Phase III Randomized Study for Breast Cancer (2006-2010)

CALGB 30607: Sub-Investigator for Phase III Randomized Study for Stage IIIB/IV NSCLC (2008-2013)

CALGB 70604: Sub-Investigator for Phase III Randomized Study for Metastatic Cancer (2009-2012)

CALGB 90202: Sub-Investigator for Phase III Randomized Study for Metastatic Cancer (2010-2011)

CALGB 70807: Sub-Investigator for Phase III Randomized Study for Metastatic Cancer (2010-2011)

CALGB 80405: Sub-Investigator for Phase III Study in Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum (2005-2012)

CCCWFU 98110: Sub-Investigator for Phase II Randomized Study for Prostate Cancer (2011-2013)

NCIC CTG MA 32: Sub-Investigator for Phase III Randomized Trial in Early Stage Breast Cancer (2011-2013)

NCCTG N0147: Sub-Investigator for Phase III Randomized Study in Patients with Stage III Colon Cancer (2007-2009)

SWOG S0702: Sub-Investigator for an Observational Multicenter Cohort Study to Assess Incidence of Osteonecrosis of the Jaw in Cancer Patients with Bone Metastases starting Zoledronic Acid. (2013 – Dec 2013)